FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue SUPPL. 1, 2001, Pages

  Naoe, Tomoki ^a   Kiyoi, Hitoshi ^a   Yamamoto, Yukiya ^a   Minami, Yosuke ^a   Yamamoto, Kazuhito ^a   Ueda, Ryuzo ^b   Saito, Hidehiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Acute myeloid leukemia; FLT3; Herbimycin A; HSP90; Molecule targeted therapy

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; CD135 ANTIGEN; ENZYME INHIBITOR; FLT3 PROTEIN, HUMAN; FLT3 PROTEIN, MOUSE; HEAT SHOCK PROTEIN 90; HERBIMYCIN; MACROCYCLIC LACTAM; ONCOPROTEIN; PROTEIN TYROSINE KINASE; QUINONE DERIVATIVE;

ACUTE DISEASE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; MYELOID LEUKEMIA; PHOSPHORYLATION; REVIEW;

ACUTE DISEASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID; MICE; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; QUINONES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 0002470404     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100301     Document Type: Article

References (35)

1. Dosil M, Wang S, Lemischka IR (1993) Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 13:6572
2. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3
3. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736
4. Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287:1969
5. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307
6. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo CF, Grignani F, Pelicci PG (1994) Acute promyelocytic leukemia: from genetics to treatment. Blood 83:10
7. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624
8. Hunter T (2000) Signalling - 2000 and beyond. Cell 100:113
9. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 11:1447
10. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333
11. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074
12. Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782
13. Lin TS, Mahajan S, Frank DA (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19:2496
14. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75:1157
15. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143
16. Mayer MP, Bukau B (1999) Molecular chaperones: the busy life of Hsp90. Curr Biol 9:R322
17. Murakami Y, Fukazawa H, Mizuno S, Uehara Y (1998) Effect of herbimycin A on tyrosine kinase receptors and platelet derived growth factor (PDGF)-induced signal transduction. Biol Pharm Bull 21:1030
18. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, Naoe T (1999) Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 104:659
19. Nakao H, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911
20. Namikawa R, Muench MO, Roncarolo MG (1996) Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis. Stem Cells 14:388
21. Rosnet O, Marchetto S, de Lapeyriere O, Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 6:1641
22. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D (1993) Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82:1110
23. Schlessinger J (2000) Cell signalling by receptor tyrosine kinases. Cell 103:211
24. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM (1996) Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839
25. Sharma SV, Agatsuma T, Nakano H (1998) Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 16:2639
26. Shiotsu Y, Neckers LM, Wortman I, An W, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96:2284
27. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459
28. Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, Sharma SV, Nakano H, Mizukami T, Hara M (1998) Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway. J Biol Chem 273:822
29. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239
30. Tobal K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ (1990) Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4:486
31. Uehara Y, Hori M, Takeuchi T, Umezawa H (1985) Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 76:672
32. Uehara Y, Murakami Y, Mizuno S, Kawai S (1988) Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 164:294
33. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Teda R, Ohno R, Naoe T (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematological malignancies. Blood 97:2434
34. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kashima K, Matsuo Y, Naoe T (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605
35. Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S, Kitamura T, Ueda R, Saito H, Naoe T (2000) In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia 14:374